HN Debrief

Hospitals and universities repurposing drugs at lower cost

  • Public Health
  • Biotech
  • Regulation
  • Economics

The article argues that many cheap wins in medicine come from testing old drugs for new diseases once patents have expired. At that point, pharma has little reason to fund large trials because the upside is mostly public benefit, not monopoly revenue. Hospitals and universities step in instead, and the headline example is eye doctors using a cancer drug for macular degeneration at far lower cost than the branded ophthalmology version.

If you work in healthcare, biotech, or employer-funded benefits, treat repurposed drugs as a real cost and access lever, but not an automatic one. The bottlenecks are evidence quality, packaging and administration safety, insurer coverage rules, and who has enough incentive to pay for the final clinical and regulatory work.

Discussion mood

Frustrated and cynical. Most comments treated drug repurposing as obviously useful but blocked by perverse incentives in pricing, patents, and regulation, with a smaller but strong corrective current pushing back on factual overstatements about off-label use and insurance coverage.

Key insights

  1. 01

    Cheap repurposing can add new safety risk

    The Avastin example shows why a 90 percent price cut does not automatically win. Using bevacizumab for macular degeneration depends on compounding pharmacies to split and repackage doses for eye injections, and that extra handling creates a contamination path that can cause endophthalmitis and permanent vision loss. One commenter also corrected that Avastin and Lucentis are not literally the same molecule, which matters because the cost gap sits alongside a real formulation and manufacturing distinction, not just pure relabeling.

    When a repurposed drug needs new packaging, dose splitting, or sterile preparation, evaluate that workflow as part of the product. Cost models that ignore compounding and administration risk can point you to the wrong answer.

      Attribution:
    • atourgates #1
    • unacorner #1
    • maxerickson #1
  2. 02

    Off-label use is already normal medicine

    Much of the confusion came from treating repurposing as if doctors need a special exception to use an old drug in a new way. In practice, off-label prescribing is routine, especially in specialties and harder cases, and insurers often cover it without checking every prescription against every labeled indication. Gabapentin for neuropathic pain was the clearest example given. The issue is not legal impossibility. It is that formal approval for a new indication often adds too little benefit for too much cost once clinicians are already prescribing the drug.

    If you are evaluating a repurposing opportunity, separate clinical adoption from label expansion. A drug can become standard practice without a new label, which changes the business case for trials, reimbursement strategy, and product support.

      Attribution:
    • Aurornis #1 #2
    • jnovek #1
    • jpk2f2 #1
    • dpark #1
  3. 03

    Approval and billing can favor the pricier variant

    The esketamine story sharpened the incentive problem. Generic ketamine is cheap, but Spravato has the labeled indication and the reimbursement pathway, so insurers and providers can end up paying for the expensive version even when commenters believe the older drug works as well or better. One commenter added a less obvious mechanism: for drugs administered in office, higher-priced products can generate more revenue for practices because reimbursement includes markup, which can tilt behavior beyond pure clinical preference.

    Do not assume payer logic will automatically route care to the lowest-cost molecule. In provider-administered drugs, reimbursement design and practice economics can overpower simple therapeutic equivalence.

      Attribution:
    • refurb #1 #2
    • dabinat #1
    • RobotToaster #1
  4. 04

    Rare diseases are not always abandoned

    A sympathetic point about Huntington's disease drew an important correction. Repurposing matters for rare diseases, but it is wrong to assume big pharma never touches them. Commenters pointed to active Huntington's programs from Roche, Regeneron, Novartis, Ionis, Alnylam, PTC, uniQure, Wave Life Sciences, and ClearPoint Neuro, along with orphan drug and accelerated approval incentives. That matters because repurposing is filling one gap, not the whole map.

    For rare disease strategy, check the current therapeutic pipeline before assuming only repurposed generics are in play. The right opportunity may be adjacency to active novel programs, not a substitute for them.

      Attribution:
    • petesergeant #1
    • unsupp0rted #1

Against the grain

  1. 01

    Insurers do not all benefit from higher prices

    The popular claim that insurers want expensive care because of medical loss ratio rules was too neat. Commenters pointed out that large parts of US coverage are self-insured employer plans where the employer, not the insurer, ultimately bears the claims cost, and public programs like Medicare, Medicaid, TriCare, and the Veterans Affairs system do not fit the same profit logic either. Price fights between providers and insurers also cut against the idea that every actor is happy with rising costs.

    When you map incentives in US healthcare, start with who actually holds the risk for a given plan. The answer changes whether lower-cost repurposed drugs have a natural institutional buyer.

      Attribution:
    • maxerickson #1 #2
    • lotsofpulp #1
  2. 02

    Public funding is not a magic replacement

    Calls to move drug development and repurposing fully into government-backed open science ran into a credible execution critique. The pushback was not a defense of current pharma pricing. It was that public agencies can become budget-driven and politically managed in ways that weaken speed, accountability, and willingness to take risk, while bad regulation can be as distortionary as monopoly pricing. That shifts the problem from ownership of research to how incentives are set inside the institution doing it.

    If you want more public or nonprofit drug development, focus on incentive design and operational accountability, not just funding source. Otherwise you can trade one set of distortions for another.

      Attribution:
    • parineum #1 #2
    • bit-anarchist #1

In plain english

Avastin ↩
A brand name for bevacizumab, a drug originally developed for cancer that is also used off-label in some eye diseases.
bevacizumab ↩
A drug that blocks blood vessel growth signals and is used in cancer care and, through repurposing, in some eye treatments.
endophthalmitis ↩
A severe infection inside the eye that can cause major vision loss or blindness.
esketamine ↩
One single-molecule form of ketamine that is sold as the branded drug Spravato for depression treatment.
ketamine ↩
An older anesthetic drug that is also used in some settings for depression and pain treatment.
Lucentis ↩
A brand name for ranibizumab, an eye drug related to bevacizumab that is approved for conditions such as macular degeneration.
macular degeneration ↩
An eye disease that damages central vision, often in older adults.
medical loss ratio ↩
A US rule that requires health insurers to spend a minimum share of premium revenue on medical care rather than administration or profit.
off-label ↩
Use of an approved drug for a condition, dose, or patient group that is not listed on its official regulatory label.
TriCare ↩
The US health coverage program for active-duty military members, retirees, and their families.

Reference links

Drug repurposing organizations and impact

Rare disease and Huntington's references

Drug pricing investigations

Clinical trial discovery

  • ClinicalTrials.gov
    Suggested as a direct way for patients to find repurposing and other clinical trials.

Research and talks on treatment discovery

Patent and policy references

Drug pricing comparisons and safety history

Alternative health and advocacy references